Industry Leading Keynote Speakers to Present at CHI's De-Risking Drug Discovery Event

Nov. 17, 2011 - PRLog -- Taking place February 21-23, 2012 in San Francisco, CA, De-Risking Drug Development is part of of CHI's Molecular Med TRI-CON. Register by November 18th & save up to $350.

De-Risking is more than just an industry buzz word, it's a philosophy for companies and leaders. David Watson and Malcolm Young put the principles of de-risking into real-life scenarios by identifying potential toxicology issues  in early discovery or implementing an entirely new approach to finding lead compounds, like network pharmacology.  Hear the incredible story of Benlysta, the first approved lupus drug in over 50 years, and how de-risking during target validation brought this drug forward, presented by David Stump.

Leading academicians, including Philip Bourne (University of California, San Diego) and  Jake Chen (University of Indiana), will identify the challenges and limitless applications of this astounding alternative to conventional drug discovery.

Presentations Include:

KEYNOTE PRESENTATION

Detoxifying the Early Portfolio
David E. Watson, Ph.D., Research Advisor, Eli Lilly & Co.

Reducing Attrition: Combining Predictive in silico and in vitro Safety Assays to Guide Design Chemistry
Thomas Schroeter, Ph.D., Senior Principal Scientist, Compound Safety Prediction, Pfizer


Integrated Safety Management Planning as a Tool for Proactive Risk Minimization
Michael Forstner, M.Sc., Ph.D., Integrated Safety Risk Manager, PDS, Roche

Safety as a Component of Target Selection
Anne Ryan, D.V.M., Ph.D., Diplomate ACVP, Executive Director, Drug Safety Research and Development, Pfizer, Inc.

Early in vitro Safety Screening: Impact in Drug Discovery
Mike Rolf, Ph.D., Associate Principal Scientist, Global Safety Assessment, AstraZeneca

Pearls (and Perils) of Staged Empirical Pre-Clinical Cardiovascular De-Risking Strategies
Gary Gintant, Ph.D., Research Fellow, Integrative Pharmacology, Chair, Abbott QT/Proarrhythmia Working Group, Abbott Laboratories

Network Polypharmacology in Systems Lead Finding
Jeremy Jenkins, Ph.D., Senior Investigator I, DMP, Quantitative Biology, Chemical Biology Informatics, Novartis Institutes for BioMedical Research

Translating Systems Biology to Systems Pharmacology: Integrating in vitro Systems Biology and Disease-PKPD Modeling to Advance the Discovery of Antibody Therapeutics
John Burke, Ph.D., Senior Principal Scientist, Head, Systems Biology and Pre-Clinical PKPD Modeling, Translational Research, Boehriniger Ingelheim Pharmaceuticals

Computational Approaches in Studying Network Pharmacology
Philip E. Bourne PhD, Professor, Pharmacology, University of California, San Diego, Associate Director, RCSB Protein Data Bank, Co-founder & Editor in Chief PLoS Computational Biology

KEYNOTE PRESENTATION

De-Risking Drug Discovery Using Network Pharmacology
Malcolm Young, Ph.D., CEO, e-Therapeutics

Modeling Drug Efficacy Using Network Pharmacology
Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University

KEYNOTE PRESENTATION

Target Validation of B-Lymphocyte Stimulator and Development of Belimumab - A Case Study
David C. Stump, M.D., Executive Vice President, Research & Development, Human Genome Sciences, Inc.

Systematic Drug Repositioning: Maximizing the Value of Drugs for Patients
Pankaj Agarwal, Ph.D., Director, Computational Biology, Molecular Discovery & Development, GlaxoSmithKline

Drug Repositioning: IP & Patent Information Every Scientist Needs
Kevin L. McLaren, Ph.D., Esq., Barnes & Thornburg LLP

Talk Title to be Announced
Natalia Novac, M.Sc., Ph.D., Scientist, Research & Development Knowledge Management, Operational Excellence, Merck Serono (invited)

Repurposing Drugs for Pediatric Rare Diseases: Ethical and Regulatory Considerations
Jason Gerson, Ph.D., Commissioner's Fellow, Office of Pediatric Therapeutics, US Food and Drug Administration

Driving Right Targets and Right Molecules to Clinic Development by Selectively Integrating Advanced Technology Platforms
Litao Zhang, Ph.D., Executive Director, Applied Biotechnology, Lead Evaluation and Mechanistic Biochemistry, Bristol-Myers Squibb

Academia Drives Innovative Target Discovery
Rathnam Chaguturu, Ph.D., Director, High-Throughput Screening Laboratories, University of Kansas; Editor-in-Chief, Combinatorial Chemistry and High-Throughput Screening

Facilitating Early Stage Projects
Lawrence R. McGee, Ph.D., Scientific Director, Medicinal Chemistry, Amgen South San Francisco

Combination Drug Profiling Strategies to De-Risk Drug Development and Improve Clinical Translation
Glenn Short, Ph.D., Director, Discovery Sciences, Zalicus

in vitro Safety Profiling during Lead Optimization to Reduce Safety Attrition
Murray Brown, Ph.D., Manager, Data Interpretation and Business Process, Screening and Compound Profiling, GlaxoSmithKline

Get more information at www.triconference.com/de-risking-drug-discovery. Register by Friday November 18th & SAVE up to $350!

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.